Intra-Cellular Therapies (ITCI) Financials

$131.87 0.00 (0.00%)

As of 04/2/2025

Annual Income Statements for Intra-Cellular Therapies

This table shows Intra-Cellular Therapies' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Net Income / (Loss) Attributable to Common Shareholders	-75	-140	-256	-284	-227	-148	-155	-98	-116	-105
Consolidated Net Income / (Loss)	-75	-140	-256	-284	-227	-148	-155	-98	-116	-105
Net Income / (Loss) Continuing Operations	-75	-140	-256	-284	-227	-148	-155	-98	-116	-105
Total Pre-Tax Income	-74	-139	-256	-284	-227	-148	-155	-99	-115	-105
Total Operating Income	-117	-159	-264	-286	-231	-154	-162	-103	-118	-106
Total Gross Profit	624	431	230	76	21	0.06	0.00	0.25	0.33	0.09
Total Revenue	681	464	250	84	23	0.06	0.00	0.25	0.33	0.09
Operating Revenue	681	464	250	84	23	0.06	0.00	0.25	0.33	-
Total Cost of Revenue	57	34	20	8.04	1.90	0.00	0.00	0.00	0.00	0.00
Operating Cost of Revenue	57	34	20	8.04	1.90	0.00	0.00	-	-	-
Total Operating Expenses	741	590	493	361	252	154	162	103	119	106
Selling, General & Admin Expense	504	410	359	273	186	65	30	24	25	18
Research & Development Expense	236	180	135	89	66	89	132	79	94	88
Total Other Income / (Expense), net	43	20	7.38	1.57	4.24	6.29	7.14	4.01	2.90	1.02
Interest & Investment Income	43	20	7.38	1.57	4.24	6.29	7.14	4.01	2.94	1.02
Income Tax Expense	0.47	0.64	0.01	0.01	0.01	0.00	0.00	-1.06	1.07	0.00
Basic Earnings per Share	($0.72)	($1.46)	($2.72)	($3.50)	($3.23)	($2.68)	($2.84)	($2.12)	($2.69)	($2.91)
Weighted Average Basic Shares Outstanding	103.13M	95.88M	94.05M	81.25M	70.36M	55.19M	54.71M	46.18M	43.24M	36.07M
Diluted Earnings per Share	($0.72)	($1.46)	($2.72)	($3.50)	($3.23)	($2.68)	($2.84)	($2.12)	($2.69)	($2.91)
Weighted Average Diluted Shares Outstanding	103.13M	95.88M	94.05M	81.25M	70.36M	55.19M	54.71M	46.18M	43.24M	36.07M
Weighted Average Basic & Diluted Shares Outstanding	106.33M	96.81M	95.28M	81.25M	70.36M	55.19M	54.71M	46.18M	43.24M	36.07M

This table shows Intra-Cellular Therapies' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-17	-26	-16	-15	-29	-24	-43	-44	-44	-54
Consolidated Net Income / (Loss)	-17	-26	-16	-15	-29	-24	-43	-44	-44	-54
Net Income / (Loss) Continuing Operations	-17	-26	-16	-15	-29	-24	-43	-44	-44	-54
Total Pre-Tax Income	-17	-26	-16	-15	-28	-24	-43	-44	-44	-54
Total Operating Income	-29	-39	-28	-21	-34	-30	-47	-48	-47	-56
Total Gross Profit	179	160	150	135	121	117	104	89	81	66
Total Revenue	199	175	161	145	132	126	111	95	88	72
Operating Revenue	199	175	161	145	132	126	111	95	88	72
Total Cost of Revenue	20	15	11	9.90	11	9.13	7.16	6.75	6.79	5.85
Operating Cost of Revenue	20	15	11	9.90	11	9.13	7.16	6.75	6.79	5.85
Total Operating Expenses	208	199	178	156	155	147	151	137	123	127
Selling, General & Admin Expense	138	132	122	113	105	105	101	99	95	88
Research & Development Expense	70	67	56	43	51	42	50	38	34	33
Total Other Income / (Expense), net	12	13	12	6.06	5.97	5.50	4.53	4.35	3.39	2.12
Interest & Investment Income	12	13	12	6.06	5.97	5.50	4.53	4.35	3.39	2.12
Income Tax Expense	-0.32	0.37	0.06	0.36	0.45	0.04	0.14	0.01	-	0.00
Basic Earnings per Share	($0.15)	($0.25)	($0.16)	($0.16)	($0.30)	($0.25)	($0.45)	($0.46)	($0.45)	($0.57)
Weighted Average Basic Shares Outstanding	103.13M	105.77M	103.72M	96.88M	95.88M	96.14M	95.95M	95.13M	94.05M	94.52M
Diluted Earnings per Share	($0.15)	($0.25)	($0.16)	($0.16)	($0.30)	($0.25)	($0.45)	($0.46)	($0.45)	($0.57)
Weighted Average Diluted Shares Outstanding	103.13M	105.77M	103.72M	96.88M	95.88M	96.14M	95.95M	95.13M	94.05M	94.52M
Weighted Average Basic & Diluted Shares Outstanding	106.33M	106.02M	105.67M	105.57M	96.81M	96.24M	96.09M	95.93M	95.28M	94.71M

This table details how cash moves in and out of Intra-Cellular Therapies' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Net Change in Cash & Equivalents	159	-0.85	57	32	-46	53	17	-11	1.48	-14
Net Cash From Operating Activities	-73	-124	-270	-260	-230	-128	-118	-80	-91	-102
Net Cash From Continuing Operating Activities	-73	-124	-270	-260	-230	-128	-118	-80	-91	-102
Net Income / (Loss) Continuing Operations	-75	-140	-256	-284	-227	-148	-155	-98	-116	-105
Consolidated Net Income / (Loss)	-75	-140	-256	-284	-227	-148	-155	-98	-116	-105
Depreciation Expense	0.51	0.53	0.66	0.53	0.53	0.48	0.37	0.21	0.20	0.14
Amortization Expense	-9.03	-8.40	0.45	-4.08	-0.65	-1.13	-0.94	0.43	0.54	0.71
Non-Cash Adjustments To Reconcile Net Income	64	52	44	34	24	22	18	15	15	11
Changes in Operating Assets and Liabilities, net	-54	-28	-59	-6.18	-27	-1.48	20	1.81	9.49	-9.41
Net Cash From Investing Activities	-335	106	-128	280	-480	177	135	-93	92	-362
Net Cash From Continuing Investing Activities	-335	106	-128	280	-480	177	135	-93	92	-362
Purchase of Property, Plant & Equipment	-0.32	-0.27	-0.78	-0.33	-0.27	-0.70	-0.39	-0.72	-0.05	-0.86
Purchase of Investments	-740	-415	-759	-225	-756	-81	-271	-521	-396	-514
Sale and/or Maturity of Investments	405	521	632	505	276	259	406	429	488	153
Net Cash From Financing Activities	568	18	455	12	664	3.24	0.69	162	0.48	450
Net Cash From Continuing Financing Activities	568	18	455	12	664	3.24	0.69	162	0.48	450
Issuance of Common Equity	543	0.00	434	0.00	653	0.00	0.00	162	0.00	450
Other Financing Activities, net	24	18	21	12	11	3.24	0.69	0.29	0.48	0.65
Cash Income Taxes Paid	1.82	0.16	0.01	0.01	0.00	0.00	0.00	0.00	1.00	0.00

This table details how cash moves in and out of Intra-Cellular Therapies' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	-157	-229	553	-7.95	48	-43	67	-73	13	58
Net Cash From Operating Activities	-13	-27	0.54	-34	-2.06	-25	-37	-60	-39	-53
Net Cash From Continuing Operating Activities	-13	-27	0.54	-34	-2.06	-25	-37	-60	-39	-53
Net Income / (Loss) Continuing Operations	-17	-26	-16	-15	-29	-24	-43	-44	-44	-54
Consolidated Net Income / (Loss)	-17	-26	-16	-15	-29	-24	-43	-44	-44	-54
Depreciation Expense	0.11	0.14	0.13	0.13	0.14	0.14	0.12	0.13	0.14	0.17
Amortization Expense	-2.99	-1.85	-1.85	-2.34	-2.54	-2.19	-1.93	-1.74	1.16	0.23
Non-Cash Adjustments To Reconcile Net Income	16	17	16	14	15	14	13	9.54	12	10
Changes in Operating Assets and Liabilities, net	-9.52	-16	2.32	-31	14	-13	-5.37	-24	-8.23	-10
Net Cash From Investing Activities	-150	-209	7.77	16	47	-20	95	-16	50	106
Net Cash From Continuing Investing Activities	-150	-209	7.77	16	47	-20	95	-16	50	106
Purchase of Property, Plant & Equipment	0.43	-0.70	-	-	-0.00	-0.27	-	-	0.03	-0.12
Purchase of Investments	-258	-313	-89	-81	-104	-136	-66	-108	-116	-91
Sale and/or Maturity of Investments	107	104	96	97	152	116	161	92	166	197
Net Cash From Financing Activities	5.61	6.73	545	9.99	3.00	2.58	8.59	3.64	2.19	5.65
Net Cash From Continuing Financing Activities	5.61	6.73	545	9.99	3.00	2.58	8.59	3.64	2.19	5.65
Other Financing Activities, net	5.61	6.73	2.09	9.99	3.00	2.58	8.59	3.64	2.19	5.65
Cash Income Taxes Paid	0.46	-	-	-	0.16	-0.01	-	-	-	-

This table presents Intra-Cellular Therapies' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Total Assets	1,367	728	755	490	717	251	357	471	389	484
Total Current Assets	1,307	668	738	467	691	230	355	469	388	483
Cash & Equivalents	307	148	149	92	60	108	55	38	49	47
Restricted Cash	1.75	1.75	1.75	1.40	1.40	0.00	-	-	-	-
Short-Term Investments	694	350	443	320	597	116	293	427	335	428
Accounts Receivable	167	114	75	20	11	0.00	-	-	0.09	0.03
Inventories, net	26	12	24	7.95	7.06	0.00	-	-	-	-
Prepaid Expenses	112	42	45	25	14	6.31	7.91	4.88	4.01	8.03
Plant, Property, & Equipment, net	1.47	1.65	1.91	1.79	2.00	2.26	1.16	1.14	0.63	0.78
Total Noncurrent Assets	58	59	15	21	24	19	0.61	1.13	0.08	0.07
Other Noncurrent Operating Assets	58	59	15	21	24	18	0.08	0.08	0.08	0.07
Total Liabilities & Shareholders' Equity	1,367	728	755	490	717	251	357	471	389	484
Total Liabilities	218	137	99	72	60	56	39	17	13	7.86
Total Current Liabilities	206	124	83	53	37	36	36	14	11	6.26
Accounts Payable	26	11	10	8.69	5.50	7.43	14	6.17	3.75	1.63
Accrued Expenses	141	81	45	17	11	16	20	6.42	5.33	3.42
Current Employee Benefit Liabilities	35	27	23	21	15	9.47	2.29	1.61	1.45	1.21
Other Current Liabilities	4.23	3.61	4.57	6.73	5.54	3.19	0.00	-	-	-
Total Noncurrent Liabilities	13	13	15	19	24	20	3.19	2.84	2.87	1.60
Other Noncurrent Operating Liabilities	13	13	15	19	24	20	0.00	-	-	-
Total Equity & Noncontrolling Interests	1,148	591	656	418	657	195	318	454	376	476
Total Preferred & Common Equity	1,148	591	656	418	657	195	318	454	376	476
Total Common Equity	1,148	591	656	418	657	195	318	454	376	476
Common Stock	2,840	2,208	2,138	1,639	1,593	905	881	862	685	670
Retained Earnings	-1,692	-1,617	-1,477	-1,221	-937	-710	-562	-407	-309	-193
Accumulated Other Comprehensive Income / (Loss)	0.19	0.10	-4.19	-0.36	0.48	0.13	-0.67	-0.80	-0.32	-0.59

This table presents Intra-Cellular Therapies' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	1,324	1,321	747	718	714	722	782
Total Current Assets	1,272	1,264	691	702	698	706	760
Cash & Equivalents	464	693	140	99	142	76	135
Restricted Cash	1.75	1.75	1.75	1.75	1.75	1.75	1.75
Short-Term Investments	542	330	336	394	371	463	493
Accounts Receivable	146	146	131	103	96	82	62
Inventories, net	24	20	16	43	42	28	24
Prepaid Expenses	94	74	66	62	46	56	44
Plant, Property, & Equipment, net	2.01	1.45	1.52	1.79	1.66	1.78	2.08
Total Noncurrent Assets	51	55	55	13	14	14	20
Other Noncurrent Operating Assets	51	55	55	13	14	14	20
Total Liabilities & Shareholders' Equity	1,324	1,321	747	718	714	722	782
Total Liabilities	180	176	148	117	107	95	97
Total Current Liabilities	166	162	135	103	92	80	77
Accounts Payable	10	18	12	11	7.73	8.44	14
Accrued Expenses	122	118	103	63	59	51	35
Current Employee Benefit Liabilities	29	22	16	25	22	17	21
Other Current Liabilities	4.20	4.17	3.64	3.58	3.56	3.53	7.25
Total Noncurrent Liabilities	14	14	13	14	14	15	19
Other Noncurrent Operating Liabilities	14	14	13	14	14	15	19
Total Equity & Noncontrolling Interests	1,145	1,145	599	601	607	628	685
Total Preferred & Common Equity	1,145	1,145	599	601	607	628	685
Total Common Equity	1,145	1,145	599	601	607	628	685
Common Stock	2,818	2,794	2,232	2,191	2,174	2,152	2,124
Retained Earnings	-1,675	-1,649	-1,632	-1,589	-1,564	-1,522	-1,433
Accumulated Other Comprehensive Income / (Loss)	1.63	-0.67	-0.43	-1.34	-2.27	-2.70	-5.50

This table displays calculated financial ratios and metrics derived from Intra-Cellular Therapies' official financial filings.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	46.62%	85.52%	198.69%	267.35%	37,537.14%	0.00%	-100.00%	-25.66%	261.96%	-84.17%
EBITDA Growth	25.12%	36.29%	9.24%	-25.02%	-49.58%	5.02%	-59.34%	13.04%	-11.96%	-242.30%
EBIT Growth	26.77%	39.54%	7.72%	-23.55%	-50.14%	5.09%	-57.79%	13.04%	-11.76%	-241.48%
NOPAT Growth	26.77%	39.54%	7.72%	-23.55%	-50.14%	5.09%	-57.79%	13.04%	-11.76%	-241.48%
Net Income Growth	46.54%	45.49%	9.81%	-25.16%	-53.67%	4.77%	-58.66%	16.02%	-11.10%	-241.44%
EPS Growth	50.68%	46.32%	22.29%	-8.36%	-20.52%	5.63%	-33.96%	21.19%	7.56%	-171.96%
Operating Cash Flow Growth	41.08%	54.03%	-4.10%	-12.81%	-79.77%	-8.31%	-46.81%	11.80%	10.78%	-348.46%
Free Cash Flow Firm Growth	3.74%	41.97%	-17.79%	-9.13%	-73.88%	-15.97%	-32.50%	3.35%	13.14%	-364.31%
Invested Capital Growth	58.77%	46.97%	1,401.44%	309.11%	93.15%	2.73%	-201.35%	-15.07%	-924.69%	111.47%
Revenue Q/Q Growth	10.94%	10.53%	33.06%	18.72%	118.95%	0.00%	-100.00%	-27.41%	25.52%	-27.81%
EBITDA Q/Q Growth	3.41%	5.43%	13.37%	-9.44%	-9.36%	0.67%	-6.76%	-4.89%	1.07%	-15.39%
EBIT Q/Q Growth	4.03%	7.71%	12.77%	-9.45%	-9.24%	0.55%	-6.51%	-4.76%	1.12%	-15.34%
NOPAT Q/Q Growth	4.03%	7.71%	12.77%	-9.45%	-9.24%	0.55%	-6.51%	-4.76%	1.12%	-15.34%
Net Income Q/Q Growth	13.54%	9.96%	14.00%	-9.66%	-9.72%	0.11%	-7.29%	-2.87%	1.15%	-14.96%
EPS Q/Q Growth	17.24%	9.32%	18.07%	-9.38%	-0.31%	0.37%	-7.17%	3.64%	1.10%	-5.05%
Operating Cash Flow Q/Q Growth	-17.72%	23.02%	11.17%	-1.94%	-16.86%	-4.83%	-3.84%	4.35%	6.75%	-39.29%
Free Cash Flow Firm Q/Q Growth	-17.17%	18.03%	6.04%	-0.68%	-16.04%	-6.27%	-3.97%	4.24%	10.46%	-46.98%
Invested Capital Q/Q Growth	6.69%	-13.39%	13.62%	-48.50%	85.75%	-1.57%	-33.33%	-70.41%	21.20%	111.74%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	91.63%	92.73%	91.83%	90.41%	91.69%	100.00%	0.00%	100.00%	100.00%	100.00%
EBITDA Margin	-18.39%	-36.02%	-104.88%	-345.14%	-1,014.11%	-255,170.22%	0.00%	-41,570.80%	-35,535.82%	-114,882.99%
Operating Margin	-17.14%	-34.32%	-105.32%	-340.90%	-1,013.58%	-254,090.46%	0.00%	-41,832.65%	-35,759.96%	-115,815.85%
EBIT Margin	-17.14%	-34.32%	-105.32%	-340.90%	-1,013.58%	-254,090.46%	0.00%	-41,832.65%	-35,759.96%	-115,815.85%
Profit (Net Income) Margin	-10.97%	-30.08%	-102.37%	-339.04%	-995.07%	-243,713.69%	0.00%	-39,771.64%	-35,205.79%	-114,698.50%
Tax Burden Percent	100.64%	100.46%	100.00%	100.00%	100.01%	100.00%	100.00%	98.93%	100.92%	100.00%
Interest Burden Percent	63.57%	87.24%	97.20%	99.45%	98.17%	95.92%	95.60%	96.10%	97.55%	99.03%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-68.84%	-144.75%	-554.40%	-18,439.60%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	-69.78%	-139.61%	-540.16%	-18,423.91%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	60.26%	122.36%	506.68%	18,386.73%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-8.58%	-22.39%	-47.72%	-52.87%	-53.30%	-57.62%	-40.18%	-23.56%	-27.34%	-35.12%
Cash Return on Invested Capital (CROIC)	-114.26%	-182.79%	-729.42%	-4,958.54%	0.00%	0.00%	0.00%	0.00%	0.00%	-8,076.39%
Operating Return on Assets (OROA)	-11.14%	-21.49%	-42.36%	-47.33%	-47.75%	-50.63%	0.00%	-23.91%	-27.09%	-34.40%
Return on Assets (ROA)	-7.13%	-18.84%	-41.18%	-47.07%	-46.88%	-48.56%	0.00%	-22.73%	-26.67%	-34.07%
Return on Common Equity (ROCE)	-8.58%	-22.39%	-47.72%	-52.87%	-53.30%	-57.62%	-40.18%	-23.56%	-27.34%	-35.12%
Return on Equity Simple (ROE_SIMPLE)	-6.50%	-23.62%	-39.06%	-67.99%	-34.56%	-75.75%	-48.83%	-21.52%	-31.01%	-22.00%
Net Operating Profit after Tax (NOPAT)	-82	-112	-185	-200	-162	-108	-114	-72	-83	-74
NOPAT Margin	-12.00%	-24.03%	-73.72%	-238.63%	-709.51%	-177,863.32%	0.00%	-29,282.85%	-25,031.97%	-81,071.10%
Net Nonoperating Expense Percent (NNEP)	0.94%	-5.14%	-14.24%	-15.69%	-14.76%	-13.97%	-10.23%	-6.08%	-7.83%	-10.16%
Return On Investment Capital (ROIC_SIMPLE)	-7.11%	-18.86%	-28.13%	-	-	-	-	-	-	-
Cost of Revenue to Revenue	8.37%	7.27%	8.17%	9.59%	8.31%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	74.10%	88.26%	143.33%	325.30%	816.92%	107,151.31%	0.00%	9,627.09%	7,486.52%	19,906.40%
R&D to Revenue	34.68%	38.79%	53.82%	106.02%	288.35%	147,039.15%	0.00%	32,305.56%	28,373.44%	96,009.45%
Operating Expenses to Revenue	108.78%	127.06%	197.15%	431.32%	1,105.27%	254,190.46%	0.00%	41,932.65%	35,859.96%	115,915.85%
Earnings before Interest and Taxes (EBIT)	-117	-159	-264	-286	-231	-154	-162	-103	-118	-106
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-125	-167	-263	-289	-231	-155	-163	-102	-118	-105
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	7.71	11.65	7.64	10.20	3.88	9.72	1.96	1.74	1.74	4.86
Price to Tangible Book Value (P/TBV)	7.71	11.65	7.64	10.20	3.88	9.72	1.96	1.74	1.74	4.86
Price to Revenue (P/Rev)	13.01	14.84	20.02	50.88	111.74	31,280.51	0.00	3,214.67	1,974.34	25,329.27
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	53.91	69.69	70.79	926.16	0.00	0.00	0.00	0.00	0.00	1,763.87
Enterprise Value to Revenue (EV/Rev)	11.53	13.77	17.65	45.94	82.85	27,584.77	0.00	1,325.89	812.87	20,128.09
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.86	-0.88	-0.94	-1.00	-1.04	-1.11	-1.05	-1.02	-1.01	-1.01
Leverage Ratio	1.20	1.19	1.16	1.12	1.14	1.19	1.07	1.04	1.03	1.03
Compound Leverage Factor	0.77	1.04	1.13	1.12	1.12	1.14	1.03	1.00	1.00	1.02
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	23.77	27.92	27.94	31.29	23.53	15.20	6.84	27.04	28.28	176.54
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	6.36	5.41	8.87	8.76	18.75	6.36	9.79	33.02	36.86	77.15
Quick Ratio	5.68	4.95	8.01	8.11	18.13	6.18	9.57	32.68	36.48	75.87
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-136	-141	-243	-206	-189	-109	-94	-71	-73	-84
Operating Cash Flow to CapEx	-22,725.78%	-46,170.63%	-34,728.28%	-79,859.69%	-86,169.66%	-18,273.01%	-30,201.58%	-11,126.43%	-186,376.17%	-11,884.80%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-1,988.54	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-2,481.10	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-2,482.43	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.65	0.63	0.40	0.14	0.05	0.00	0.00	0.00	0.00	0.00
Accounts Receivable Turnover	4.85	4.91	5.25	5.42	0.00	0.00	0.00	0.00	5.29	2.22
Inventory Turnover	3.00	1.90	1.28	1.07	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	436.16	260.37	135.16	44.23	10.72	0.04	0.00	0.28	0.47	0.22
Accounts Payable Turnover	3.04	3.09	2.14	1.13	0.29	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	75.19	74.36	69.51	67.34	0.00	0.00	0.00	0.00	68.98	164.32
Days Inventory Outstanding (DIO)	121.52	192.35	284.49	340.80	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	120.23	118.15	170.39	322.36	1,244.93	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	76.49	148.56	183.62	85.77	-1,244.93	0.00	0.00	0.00	68.98	164.32
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	146	92	62	4.16	-1.99	-29	-30	-9.89	-8.60	1.04
Invested Capital Turnover	5.74	6.03	7.52	77.27	-1.47	0.00	0.00	-0.03	-0.09	-0.02
Increase / (Decrease) in Invested Capital	54	29	58	6.14	27	0.81	-20	-1.30	-9.64	10
Enterprise Value (EV)	7,852	6,393	4,418	3,850	1,890	1,672	276	326	269	1,839
Market Capitalization	8,855	6,893	5,012	4,264	2,549	1,896	623	790	653	2,314
Book Value per Share	$10.83	$6.15	$6.93	$5.13	$8.19	$3.53	$5.81	$8.33	$8.68	$11.07
Tangible Book Value per Share	$10.83	$6.15	$6.93	$5.13	$8.19	$3.53	$5.81	$8.33	$8.68	$11.07
Total Capital	1,148	591	656	418	657	195	318	454	376	476
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-1,003	-500	-594	-414	-659	-224	-348	-464	-384	-475
Capital Expenditures (CapEx)	0.32	0.27	0.78	0.33	0.27	0.70	0.39	0.72	0.05	0.86
Debt-free, Cash-free Net Working Capital (DFCFNWC)	99	45	61	0.19	-4.80	-30	-28	-9.33	-6.43	1.79
Debt-free Net Working Capital (DFNWC)	1,102	544	655	414	654	194	319	455	378	477
Net Working Capital (NWC)	1,102	544	655	414	654	194	319	455	378	477
Net Nonoperating Expense (NNE)	-7.03	28	72	84	65	40	42	26	34	31
Net Nonoperating Obligations (NNO)	-1,003	-500	-594	-414	-659	-224	-348	-464	-384	-475
Total Depreciation and Amortization (D&A)	-8.52	-7.87	1.10	-3.55	-0.12	-0.65	-0.57	0.64	0.74	0.85
Debt-free, Cash-free Net Working Capital to Revenue	14.52%	9.60%	24.40%	0.23%	-21.03%	-49,346.24%	0.00%	-3,793.29%	-1,945.23%	1,961.71%
Debt-free Net Working Capital to Revenue	161.81%	117.20%	261.56%	493.93%	2,867.01%	320,228.25%	0.00%	185,084.31%	114,201.84%	522,079.40%
Net Working Capital to Revenue	161.81%	117.20%	261.56%	493.93%	2,867.01%	320,228.25%	0.00%	185,084.31%	114,201.84%	522,079.40%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.72)	($1.46)	($2.72)	($3.50)	($3.23)	($2.68)	($2.84)	($2.12)	($2.69)	($2.91)
Adjusted Weighted Average Basic Shares Outstanding	103.13M	95.88M	94.05M	93.59M	80.92M	66.13M	55.12M	54.68M	43.41M	43.21M
Adjusted Diluted Earnings per Share	($0.72)	($1.46)	($2.72)	($3.50)	($3.23)	($2.68)	($2.84)	($2.12)	($2.69)	($2.91)
Adjusted Weighted Average Diluted Shares Outstanding	103.13M	95.88M	94.05M	93.59M	80.92M	66.13M	55.12M	54.68M	43.41M	43.21M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	($3.50)	($3.23)	($2.68)	($2.84)	($2.12)	($2.69)	($2.91)
Adjusted Weighted Average Basic & Diluted Shares Outstanding	106.33M	96.81M	95.28M	81.25M	70.36M	55.19M	54.71M	46.18M	43.24M	36.07M
Normalized Net Operating Profit after Tax (NOPAT)	-82	-112	-185	-200	-162	-108	-114	-72	-83	-74
Normalized NOPAT Margin	-12.00%	-24.03%	-73.72%	-238.63%	-709.51%	-177,863.32%	0.00%	-29,282.85%	-25,031.97%	-81,071.10%
Pre Tax Income Margin	-10.90%	-29.94%	-102.37%	-339.03%	-995.01%	-243,711.05%	0.00%	-40,203.17%	-34,883.55%	-114,696.75%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-3,215.22	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-2,250.65	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-3,216.55	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-2,251.98	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-0.72%

This table displays calculated financial ratios and metrics derived from Intra-Cellular Therapies' official financial filings.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	50.81%	39.00%	45.67%	52.00%	50.34%	75.56%	99.34%	172.33%	242.29%	223.64%
EBITDA Growth	12.13%	-27.67%	39.89%	53.67%	20.83%	42.48%	42.11%	34.71%	46.78%	29.90%
EBIT Growth	14.37%	-30.75%	41.24%	56.70%	28.08%	46.59%	46.34%	33.40%	44.87%	28.06%
NOPAT Growth	14.37%	-30.75%	41.24%	56.70%	28.08%	46.59%	46.34%	33.40%	44.87%	28.06%
Net Income Growth	40.92%	-8.52%	62.09%	65.39%	35.09%	54.66%	50.60%	38.92%	48.65%	30.43%
EPS Growth	50.00%	0.00%	64.44%	65.22%	33.33%	56.14%	51.09%	41.03%	57.14%	40.00%
Operating Cash Flow Growth	-534.55%	-4.97%	101.47%	43.20%	94.74%	52.63%	61.18%	27.50%	46.45%	32.69%
Free Cash Flow Firm Growth	-39.79%	19.48%	43.21%	51.11%	41.84%	16.34%	22.92%	-41.83%	-37.83%	-12.67%
Invested Capital Growth	58.77%	28.90%	29.70%	40.13%	46.97%	92.81%	115.24%	346.89%	1,401.44%	580.49%
Revenue Q/Q Growth	13.60%	8.67%	11.41%	9.66%	4.70%	13.88%	16.25%	8.46%	22.26%	29.31%
EBITDA Q/Q Growth	20.92%	-37.73%	-27.13%	36.54%	-14.89%	35.15%	2.01%	-8.44%	16.52%	34.73%
EBIT Q/Q Growth	24.84%	-40.13%	-32.32%	38.55%	-14.75%	37.02%	2.51%	-2.07%	14.77%	36.73%
NOPAT Q/Q Growth	24.84%	-40.13%	-32.32%	38.55%	-14.75%	37.02%	2.51%	-2.07%	14.77%	36.73%
Net Income Q/Q Growth	35.86%	-62.29%	-6.38%	46.65%	-17.81%	43.30%	2.88%	-0.06%	17.72%	38.21%
EPS Q/Q Growth	40.00%	-56.25%	0.00%	46.67%	-20.00%	44.44%	2.17%	-2.22%	21.05%	38.04%
Operating Cash Flow Q/Q Growth	50.70%	-4,993.91%	101.59%	-1,555.31%	91.84%	31.34%	38.73%	-53.26%	26.54%	43.72%
Free Cash Flow Firm Q/Q Growth	-28.64%	-23.30%	5.57%	6.67%	25.90%	13.04%	18.70%	-11.02%	-6.58%	19.88%
Invested Capital Q/Q Growth	6.69%	13.80%	-1.78%	33.13%	-13.39%	14.51%	6.12%	39.63%	13.62%	27.84%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	89.76%	91.27%	92.96%	93.17%	91.90%	92.76%	93.53%	92.92%	92.27%	91.86%
EBITDA Margin	-16.10%	-23.13%	-18.25%	-15.99%	-27.63%	-25.18%	-44.22%	-52.46%	-52.47%	-76.85%
Operating Margin	-14.66%	-22.15%	-17.18%	-14.46%	-25.81%	-23.55%	-42.58%	-50.78%	-53.96%	-77.40%
EBIT Margin	-14.66%	-22.15%	-17.18%	-14.46%	-25.81%	-23.55%	-42.58%	-50.78%	-53.96%	-77.40%
Profit (Net Income) Margin	-8.48%	-15.01%	-10.05%	-10.52%	-21.63%	-19.23%	-38.62%	-46.22%	-50.10%	-74.45%
Tax Burden Percent	98.16%	101.44%	100.35%	102.41%	101.59%	100.18%	100.32%	100.02%	100.00%	100.00%
Interest Burden Percent	58.92%	66.80%	58.30%	71.06%	82.50%	81.50%	90.40%	91.01%	92.86%	96.19%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-58.85%	-78.51%	-63.91%	-49.72%	-108.86%	-86.12%	-161.01%	-207.03%	-284.04%	-323.55%
ROIC Less NNEP Spread (ROIC-NNEP)	-59.32%	-78.63%	-64.32%	-49.61%	-108.00%	-85.51%	-159.38%	-205.48%	-281.88%	-320.93%
Return on Net Nonoperating Assets (RNNOA)	51.23%	67.71%	56.52%	41.15%	94.65%	74.81%	143.14%	190.05%	264.41%	303.68%
Return on Equity (ROE)	-7.62%	-10.80%	-7.39%	-8.57%	-14.21%	-11.31%	-17.88%	-16.98%	-19.62%	-19.88%
Cash Return on Invested Capital (CROIC)	-114.26%	-95.48%	-99.99%	-121.69%	-182.79%	-213.71%	-278.39%	-441.05%	-729.42%	-820.31%
Operating Return on Assets (OROA)	-9.52%	-13.31%	-9.53%	-10.12%	-16.16%	-13.20%	-20.42%	-19.83%	-21.70%	-21.75%
Return on Assets (ROA)	-5.51%	-9.02%	-5.58%	-7.36%	-13.55%	-10.77%	-18.52%	-18.05%	-20.15%	-20.92%
Return on Common Equity (ROCE)	-7.62%	-10.80%	-7.39%	-8.57%	-14.21%	-11.31%	-17.88%	-16.98%	-19.62%	-19.88%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-7.54%	-7.37%	-18.49%	0.00%	-25.82%	-30.37%	-36.36%	0.00%	-43.47%
Net Operating Profit after Tax (NOPAT)	-20	-27	-19	-15	-24	-21	-33	-34	-33	-39
NOPAT Margin	-10.26%	-15.51%	-12.02%	-10.12%	-18.07%	-16.48%	-29.81%	-35.54%	-37.77%	-54.18%
Net Nonoperating Expense Percent (NNEP)	0.47%	0.12%	0.41%	-0.11%	-0.86%	-0.61%	-1.63%	-1.55%	-2.15%	-2.63%
Return On Investment Capital (ROIC_SIMPLE)	-1.78%	-	-	-	-4.04%	-	-	-	-5.06%	-
Cost of Revenue to Revenue	10.24%	8.73%	7.04%	6.83%	8.10%	7.24%	6.47%	7.08%	7.73%	8.14%
SG&A Expenses to Revenue	69.13%	75.32%	75.33%	78.06%	79.27%	83.38%	91.17%	103.80%	107.70%	122.97%
R&D to Revenue	35.28%	38.10%	34.81%	29.57%	38.44%	32.93%	44.94%	39.90%	38.54%	46.30%
Operating Expenses to Revenue	104.41%	113.43%	110.14%	107.63%	117.71%	116.31%	136.12%	143.69%	139.57%	177.40%
Earnings before Interest and Taxes (EBIT)	-29	-39	-28	-21	-34	-30	-47	-48	-47	-56
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-32	-41	-29	-23	-37	-32	-49	-50	-46	-55
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	7.71	6.75	6.32	11.11	11.65	8.33	10.01	8.22	7.64	6.41
Price to Tangible Book Value (P/TBV)	7.71	6.75	6.32	11.11	11.65	8.33	10.01	8.22	7.64	6.41
Price to Revenue (P/Rev)	13.01	12.60	12.81	12.96	14.84	11.91	16.60	16.61	20.02	23.35
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	53.91	49.25	51.74	50.62	69.69	42.59	60.11	53.00	70.79	68.49
Enterprise Value to Revenue (EV/Rev)	11.53	10.95	10.99	12.03	13.77	10.74	15.20	14.87	17.65	20.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.86	-0.86	-0.88	-0.83	-0.88	-0.87	-0.90	-0.92	-0.94	-0.95
Leverage Ratio	1.20	1.17	1.16	1.20	1.19	1.17	1.15	1.12	1.16	1.14
Compound Leverage Factor	0.71	0.78	0.68	0.85	0.98	0.95	1.04	1.02	1.08	1.10
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	23.98	25.42	24.28	25.51	28.49	24.02	32.46	31.04	28.89	25.78
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	6.36	7.66	7.81	5.12	5.41	6.81	7.58	8.87	8.87	9.81
Quick Ratio	5.68	6.94	7.22	4.50	4.95	5.78	6.61	7.79	8.01	8.92
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-74	-58	-47	-50	-53	-72	-83	-102	-91	-86
Operating Cash Flow to CapEx	0.00%	-3,811.06%	0.00%	0.00%	-206,100.00%	-9,429.10%	0.00%	0.00%	0.00%	-45,599.15%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.65	0.60	0.56	0.70	0.63	0.56	0.48	0.39	0.40	0.28
Accounts Receivable Turnover	4.85	4.94	4.67	4.83	4.91	5.12	5.12	5.43	5.25	4.79
Inventory Turnover	3.00	1.42	1.33	1.67	1.90	0.90	0.79	1.33	1.28	1.02
Fixed Asset Turnover	436.16	323.53	364.09	311.38	260.37	216.96	192.90	156.72	135.16	93.58
Accounts Payable Turnover	3.04	4.51	3.25	3.69	3.09	2.40	2.87	2.39	2.14	1.23
Days Sales Outstanding (DSO)	75.19	73.83	78.13	75.53	74.36	71.33	71.31	67.20	69.51	76.13
Days Inventory Outstanding (DIO)	121.52	256.89	275.30	219.09	192.35	407.34	459.94	275.08	284.49	357.97
Days Payable Outstanding (DPO)	120.23	80.90	112.30	98.80	118.15	151.92	127.03	152.52	170.39	295.82
Cash Conversion Cycle (CCC)	76.49	249.82	241.13	195.82	148.56	326.75	404.22	189.76	183.62	138.27
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	146	137	120	122	92	106	92	87	62	55
Invested Capital Turnover	5.74	5.06	5.31	4.91	6.03	5.22	5.40	5.82	7.52	5.97
Increase / (Decrease) in Invested Capital	54	31	27	35	29	51	50	68	58	47
Enterprise Value (EV)	7,852	6,723	6,206	6,182	6,393	4,511	5,559	4,619	4,418	3,762
Market Capitalization	8,855	7,732	7,231	6,660	6,893	5,005	6,074	5,159	5,012	4,393
Book Value per Share	$10.83	$10.83	$10.84	$6.19	$6.15	$6.25	$6.33	$6.59	$6.93	$7.26
Tangible Book Value per Share	$10.83	$10.83	$10.84	$6.19	$6.15	$6.25	$6.33	$6.59	$6.93	$7.26
Total Capital	1,148	1,145	1,145	599	591	601	607	628	656	685
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-1,003	-1,008	-1,025	-477	-500	-495	-515	-540	-594	-630
Capital Expenditures (CapEx)	-0.43	0.70	0.00	0.00	0.00	0.27	0.00	0.00	-0.03	0.12
Debt-free, Cash-free Net Working Capital (DFCFNWC)	99	97	78	78	45	105	91	86	61	52
Debt-free Net Working Capital (DFNWC)	1,102	1,106	1,102	556	544	599	606	627	655	682
Net Working Capital (NWC)	1,102	1,106	1,102	556	544	599	606	627	655	682
Net Nonoperating Expense (NNE)	-3.55	-0.87	-3.19	0.58	4.71	3.46	9.76	10	11	15
Net Nonoperating Obligations (NNO)	-1,003	-1,008	-1,025	-477	-500	-495	-515	-540	-594	-630
Total Depreciation and Amortization (D&A)	-2.88	-1.71	-1.72	-2.21	-2.40	-2.06	-1.81	-1.60	1.31	0.40
Debt-free, Cash-free Net Working Capital to Revenue	14.52%	15.85%	13.78%	15.25%	9.60%	24.89%	24.98%	27.70%	24.40%	27.57%
Debt-free Net Working Capital to Revenue	161.81%	180.15%	195.29%	108.13%	117.20%	142.65%	165.65%	201.69%	261.56%	362.73%
Net Working Capital to Revenue	161.81%	180.15%	195.29%	108.13%	117.20%	142.65%	165.65%	201.69%	261.56%	362.73%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.15)	($0.25)	($0.16)	($0.16)	($0.30)	($0.25)	($0.45)	($0.46)	($0.45)	($0.57)
Adjusted Weighted Average Basic Shares Outstanding	103.13M	105.77M	103.72M	96.88M	95.88M	96.14M	95.95M	95.13M	94.05M	94.52M
Adjusted Diluted Earnings per Share	($0.15)	($0.25)	($0.16)	($0.16)	($0.30)	($0.25)	($0.45)	($0.46)	($0.45)	($0.57)
Adjusted Weighted Average Diluted Shares Outstanding	103.13M	105.77M	103.72M	96.88M	95.88M	96.14M	95.95M	95.13M	94.05M	94.52M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	106.33M	106.02M	105.67M	105.57M	96.81M	96.24M	96.09M	95.93M	95.28M	94.71M
Normalized Net Operating Profit after Tax (NOPAT)	-20	-27	-19	-15	-24	-21	-33	-34	-33	-39
Normalized NOPAT Margin	-10.26%	-15.51%	-12.02%	-10.12%	-18.07%	-16.48%	-29.81%	-35.54%	-37.77%	-54.18%
Pre Tax Income Margin	-8.63%	-14.80%	-10.02%	-10.28%	-21.30%	-19.19%	-38.49%	-46.21%	-50.10%	-74.45%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Intra-Cellular Therapies' Financials

When does Intra-Cellular Therapies's fiscal year end?

According to the most recent income statement we have on file, Intra-Cellular Therapies' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Intra-Cellular Therapies' net income changed over the last 9 years?

Intra-Cellular Therapies' net income appears to be on an upward trend, with a most recent value of -$74.68 million in 2024, falling from -$104.79 million in 2015. The previous period was -$139.67 million in 2023. View Intra-Cellular Therapies' forecast to see where analysts expect Intra-Cellular Therapies to go next.

What is Intra-Cellular Therapies's operating income?

Intra-Cellular Therapies's total operating income in 2024 was -$116.72 million, based on the following breakdown:

Total Gross Profit: $623.89 million
Total Operating Expenses: $740.61 million

How has Intra-Cellular Therapies revenue changed over the last 9 years?

Over the last 9 years, Intra-Cellular Therapies' total revenue changed from $91.36 thousand in 2015 to $680.85 million in 2024, a change of 745,108.2%.

How much debt does Intra-Cellular Therapies have?

Intra-Cellular Therapies' total liabilities were at $218.45 million at the end of 2024, a 59.6% increase from 2023, and a 2,679.1% increase since 2015.

How much cash does Intra-Cellular Therapies have?

In the past 9 years, Intra-Cellular Therapies' cash and equivalents has ranged from $37.79 million in 2017 to $306.95 million in 2024, and is currently $306.95 million as of their latest financial filing in 2024.

How has Intra-Cellular Therapies' book value per share changed over the last 9 years?

Over the last 9 years, Intra-Cellular Therapies' book value per share changed from 11.07 in 2015 to 10.83 in 2024, a change of -2.1%.

Related Companies

This page (NASDAQ:ITCI) was last updated on 5/21/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Intra-Cellular Therapies (ITCI) Financials

Frequently Asked Questions About Intra-Cellular Therapies' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Intra-Cellular Therapies (ITCI) Financials

Annual Income Statements for Intra-Cellular Therapies

Quarterly Income Statements for Intra-Cellular Therapies

Annual Cash Flow Statements for Intra-Cellular Therapies

Quarterly Cash Flow Statements for Intra-Cellular Therapies

Annual Balance Sheets for Intra-Cellular Therapies

Quarterly Balance Sheets for Intra-Cellular Therapies

Annual Metrics And Ratios for Intra-Cellular Therapies

Quarterly Metrics And Ratios for Intra-Cellular Therapies

Frequently Asked Questions About Intra-Cellular Therapies' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools